RET inhibitor
RET kinase inhibitor (selective)
- Selective for RET fusions (lung, thyroid) and RET mutations (medullary thyroid cancer)
- Selectivity spares VEGFR → less hypertension than the older multikinase RET agents
- Hypertension, transaminitis and QT prolongation are still monitored
- Selective for RET fusions (lung, thyroid) and RET mutations (medullary thyroid cancer)
- Selectivity spares VEGFR → less hypertension than the older multikinase RET agents
- Hypertension, transaminitis and QT prolongation are still monitored
Drugs with this mechanism (1)
- Pralsetinib — Selective RET inhibitor for RET-driven cancers; monitor for hypertension, hepatotoxicity, and pneumonitis.
All mechanisms · Open RET inhibitor in the interactive console ↗